Correlation among [18F]fluorodeoxyglucose positron emission tomography/computed tomography, cancer antigen 27.29, and circulating tumor cell testing in metastatic breast cancer

Clinical Breast Cancer

Volumn 8, Issue 4, 2008, Pages 357-361

  Saad, Ayman ^a   Kanate, Abraham ^b   Sehbai, Aasim ^a   Marano, Gary ^b   Hobbs, Gerry ^b   Abraham, Jame ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hematogenous; MUC1; Polymorphic epithelial mucins; Serologic tumor markers

Indexed keywords

CA 27-29 ANTIGEN; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER TEST; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; METASTATIC BREAST CANCER; BLOOD; BREAST TUMOR; COMPUTER ASSISTED TOMOGRAPHY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR EMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 53449087876     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.042     Document Type: Article

References (16)

1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1:571-3.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
3. Kurian S, Qazilbash M, Fay J, et al. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit. Breast J 2006; 12:531-5.
4. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10:6897-904.
5. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351:781-91.
6. Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006; 12:6403-9.
7. Price MR, Hudecz F, O'Sullivan C, et al. Immunological and structural features of the protein core of human polymorphic epithelial mucin. Mol Immunol 1990; 27:795-802.
8. Briggs S, Price MR, Tendler SJ. Immune recognition of linear epitopes in peptide fragments of epithelial mucins. Immunology 1991; 73:505-7.
9. Klee GG, Schreiber WE. MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen? Arch Pathol Lab Med 2004; 128:1131-5.
10. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354:496-507.
11. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18)F]- fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18:1676-88.
12. Kagan M, Howard D, Bendele T, et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay 2002; 25:104-10.
13. Erasmus JJ, Gladish GW, Broemeling L, et al. Interobservet and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003; 21:2574-82.
14. Paterson, AH, Cyr M, Szafran O, et al. Response to treatment and its influence on survival in metastatic breast cancer. Am J Clin Oncol 1985; 8:283-92.
15. Colomer R, Ruibal A, Salvador L. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 1989; 64:1674-81.
16. Saad AA, Rikhye S, Kanate A, et al. Correlation among [18-F]FDG-PET/CT, tumor marker CA 27.29, and circulating tumor cells in metastatic breast cancer. J Clin Oncol 2007; 25(18 suppl):573s (Abstract 10533).